David J. Brayden
| David J. Brayden | |
|---|---|
| Born | |
| 💼 Occupation | Pharmaceutical scientist, researcher, and academic |
David J. Brayden is a pharmaceutical scientist, researcher, and academic. He is a full professor of advanced drug delivery at the University College Dublin (UCD).
Brayden's research has focused on peptide delivery across intestinal and buccal epithelia, utilizing nanoparticle and permeation enhancer constructs for oral peptide administration, evaluating high-content toxicology in cells, and developing nanoparticle formulations for intra-articular injection for arthritis.
Brayden is a fellow of the Controlled Release Society and a member of the Royal Irish Academy.
Education
Brayden completed his B.Sc. in Pharmacology and Toxicology and M.Sc. in Pharmacology at UCD in 1984 and 1985, respectively. He later earned an M.Phil. in Pharmacology in 1986 and a Ph.D. in Pharmacology in 1989 from the University of Cambridge.[1]
Career
From 1988 to 1989, Brayden worked as a research assistant at the University of Cambridge. He undertook a postdoctoral fellowship at Stanford University in 1989. In 2001, he joined UCD as an assistant professor and was promoted to associate professor in 2005, to professor in 2006, and to full professor in 2014.[2]
Between 2003 and 2006, Brayden was the co-founding chairperson of the UK–Ireland Chapter of the Controlled Release Society.[1] He was employed as the Deputy Coordinator of an EU 7th Framework grant on oral nanomedicines, TRANS-INT. He holds the role of Co-lead principal Investigator at CÚRAM, the Research Ireland Centre for Medical Devices,[2] and is the coordinator of the Horizon Europe Consortium, BUCCAL-PEP.[3] He is the Field Chief Editor of Frontiers in Drug Delivery.[4]
Research
Brayden's research has centered on advanced drug delivery systems[5] and strategies to improve the delivery of macromolecules.[6] A central theme of his work has focused on poor intestinal permeability of macromolecules,[7] degradation of peptides in the gastrointestinal tract,[8] and the effects of reduced oral bioavailability on therapeutic effectiveness.[9] His studies have investigated intestinal permeation enhancers to promote peptide absorption,[10] technologies aimed at enhancing intestinal absorption,[5] and methods to reduce the need for injectable drug administration.[11]
Another major strand of Brayden's work has explored methods such as pH-sensitive encapsulation for delivering macromolecules directly to intestinal regions.[12] These approaches included formulation-based strategies to improve mucosal transport of therapeutic peptides,[13] enabling controlled and site-specific drug release.[12] He has also contributed to translational and interdisciplinary research in drug delivery technologies. He worked on oral peptide drug delivery using silica-based nanotechnology systems[14] and explored biomaterial-based nanocomplexes for drug delivery applications.[15] He documented that intra-articular nanocomplexes entrapping selected molecules reduce inflammation by modulating inflammatory gene expression.[16] His research has also focused on the development of oral formulations of peptide-based therapies as alternatives to injectable administration.[11]
Awards and honors
- Fellow, Controlled Release Society[17]
- Fellow, American Association of Pharmaceutical Scientists[18]
- 2024 – Member, Royal Irish Academy[19]
Selected articles
- McCartney, Fiona; Jannin, Vincent; Chevrier, Stéphanie; Boulghobra, Hakime; Hristov, Delyan R.; Ritter, Nicolas; Miolane, Cédric; Chavant, Yann; Demarne, Frédéric; Brayden, David J. (2019). "Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies". Journal of Controlled Release. 310: 115–126. doi:10.1016/j.jconrel.2019.08.008. PMID 31401199.
- Hristov, Delyan; McCartney, Fiona; Beirne, Jason; Mahon, Eugene; Reid, Stephanie; Bhattacharjee, Sourav; Penarier, Geraldine; Werner, Ulrich; Bazile, Didier; Brayden, David J. (2020). "Silica-coated nanoparticles with a core of zinc, l-Arginine, and a peptide designed for oral delivery". ACS Applied Materials & Interfaces. 12 (1): 1257–1269. Bibcode:2020AAMI...12.1257H. doi:10.1021/acsami.9b16104. PMID 31802658.
- Twarog, Caroline; Liu, Kai; O'Brien, Peter J.; Dawson, Kenneth A.; Fattal, Elias; Illel, Brigitte; Brayden, David J. (2020). "A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C10)". European Journal of Pharmaceutics and Biopharmaceutics. 152: 95–107. doi:10.1016/j.ejpb.2020.04.023. PMID 32387703 Check
|pmid=value (help). - Khandelia, Rumi; Hodgkinson, Tom; Crean, Daniel; Brougham, Dermot F.; Scholz, Dimitri; Ibrahim, Hossam; Quinn, Susan J.; Rodriguez, Brian J.; Kennedy, Oran D.; O’Byrne, John M.; Brayden, David J. (2024). "Reproducible synthesis of biocompatible albumin nanoparticles designed for intra-articular administration of celecoxib to treat osteoarthritis". ACS Applied Materials & Interfaces. 16 (12): 14633–14644. Bibcode:2024AAMI...1614633K. doi:10.1021/acsami.4c02243. PMC 10982941 Check
|pmc=value (help). PMID 38483312 Check|pmid=value (help). - Karki, Sandeep; Malhotra, Sahil; Ijaz, Muhammad; Rollet, Nicolas; O'Cearbhaill, Eoin D.; Bini, Estela; Brayden, David J. (2026). "A pullulan-based bilayer film for buccal delivery of a GLP-1 peptide analogue". Carbohydrate Polymers. 380. doi:10.1016/j.carbpol.2026.125064. PMID 41831981 Check
|pmid=value (help). Unknown parameter|article-number=ignored (help)
References
- ↑ 1.0 1.1 "Curriculum vitae". United States Patent and Trademark Office Patent Trial and Appeal Board Case Tracking System. Retrieved May 4, 2026.
- ↑ 2.0 2.1 "David Brayden". University College Dublin People Directory. Retrieved May 4, 2026.
- ↑ "University College Dublin". Buccal PEP. 27 November 2018. Retrieved May 7, 2026.
- ↑ "Editorial board". Frontiers in Drug Delivery. Retrieved May 4, 2026.
- ↑ 5.0 5.1 Gonçalves, Raquel F. S.; Martins, Joana T.; Duarte, Catarina M. M.; Vicente, António A.; Pinheiro, Ana C. (2018). "Advances in nutraceutical delivery systems: From formulation design for bioavailability enhancement to efficacy and safety evaluation". Trends in Food Science & Technology. 78: 287. doi:10.1016/j.tifs.2018.06.011. hdl:1822/55331.
- ↑ McClements, David Julian (2018). "Encapsulation, protection, and delivery of bioactive proteins and peptides using nanoparticle and microparticle systems: A review". Advances in Colloid and Interface Science. 253: 9. Bibcode:2018AdCIS.253....1M. doi:10.1016/j.cis.2018.02.002. PMID 29478671.
- ↑ Bucheit, John D.; Pamulapati, Lauren G.; Carter, Nicole; Malloy, Kevin; Dixon, Dave L.; Sisson, Evan M. (2020). "Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist". Diabetes Technology & Therapeutics. 22 (1): 11. doi:10.1089/dia.2019.0185. PMID 31436480.
- ↑ Lucana, Maria C.; Arruga, Yolanda; Petrachi, Emilia; Roig, Albert; Lucchi, Roberta; Oller-Salvia, Benjamí (2021). "Protease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics". Pharmaceutics. 13 (12): 2. doi:10.3390/pharmaceutics13122065. PMC 8708026 Check
|pmc=value (help). PMID 34959346 Check|pmid=value (help). - ↑ Luo, Zhi; Paunović, Nevena; Leroux, Jean-Christophe (2021). "Physical methods for enhancing drug absorption from the gastrointestinal tract". Advanced Drug Delivery Reviews. 175: 3. doi:10.1016/j.addr.2021.05.024. PMID 34052229 Check
|pmid=value (help). Unknown parameter|article-number=ignored (help) - ↑ Mahapatra, Manoj Kumar; Karuppasamy, Muthukumar; Sahoo, Biswa Mohan (2022). "Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes". Reviews in Endocrine & Metabolic Disorders. 23 (3): 523. doi:10.1007/s11154-021-09699-1. PMC 8736331 Check
|pmc=value (help). PMID 34993760 Check|pmid=value (help). - ↑ 11.0 11.1 Guo, Wanjun; Xu, Zheng; Zou, Haixia; Li, Feng; Li, Yao; et al. (2023). "Discovery of ecnoglutide – A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog". Molecular Metabolism. 75: 9. doi:10.1016/j.molmet.2023.101762. PMC 10339203 Check
|pmc=value (help). PMID 37364710 Check|pmid=value (help). Unknown parameter|article-number=ignored (help) - ↑ 12.0 12.1 Fagihi, Megren H. A.; Bhattacharjee, Sourav (2022). "Amyloid Fibrillation of Insulin: Amelioration Strategies and Implications for Translation". ACS Pharmacology & Translational Science. 5 (11): 1056. doi:10.1021/acsptsci.2c00174. PMC 9667547 Check
|pmc=value (help). PMID 36407954 Check|pmid=value (help). - ↑ Bashir, Shazia; Fitaihi, Rawan; Abdelhakim, Hend E. (2023). "Advances in formulation and manufacturing strategies for the delivery of therapeutic proteins and peptides in orally disintegrating dosage forms". European Journal of Pharmaceutical Sciences. 182: 6. doi:10.1016/j.ejps.2023.106374. PMID 36623699 Check
|pmid=value (help). Unknown parameter|article-number=ignored (help) - ↑ Durán-Lobato, Matilde; López-Estévez, Ana María; Cordeiro, Ana Sara; Dacoba, Tamara G.; Crecente-Campo, José; Torres, Dolores; Alonso, María José (2021). "Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape". Advanced Drug Delivery Reviews. 176: 6. doi:10.1016/j.addr.2021.113899. PMID 34314784 Check
|pmid=value (help). Unknown parameter|article-number=ignored (help) - ↑ Jain, Shardool; Doshi, Aatman S.; Iyer, Arun K.; Amiji, Mansoor M. (2013). "Multifunctional nanoparticles for targeting cancer and inflammatory diseases". Journal of Drug Targeting. 21 (10): 888–903. doi:10.3109/1061186X.2013.832769. PMID 24024598.
- ↑ Yuan, X. L.; Meng, H. Y.; Wang, Y. C.; Peng, J.; Guo, Q. Y.; Wang, A. Y.; Lu, S. B. (2014). "Bone–cartilage interface crosstalk in osteoarthritis: potential pathways and future therapeutic strategies". Osteoarthritis and Cartilage. 22 (8): 1084. doi:10.1016/j.joca.2014.05.023. PMID 24928319.
- ↑ "College of Fellows award recipients". Controlled Release Society. Retrieved May 4, 2026.
- ↑ "AAPS fellows list". American Association of Pharmaceutical Scientists. Retrieved May 4, 2026.
- ↑ "Professor David J Brayden". Royal Irish Academy. 4 March 2026. Retrieved May 4, 2026.
External links
- David J. Brayden publications indexed by Google Scholar
This article "David J. Brayden" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:David J. Brayden. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
